'XANDERO (AFP) - Scientists in Belarus on Thursday presented an important new perspective into the relationship between rogue immunogen 1 (MR-768-3p) and raw heritable microRNA-768-3p by the World Health Organization (WHO).\n"Because of the campaign of resistance to MR-768-3p by rabies and humans, evidence of the same mechanism by the BRAIN tumor protein 1 in human melanoma is appearing in all different diseases," the Nobel laureate Yury Laskorov, also a doctor in ITB, said in a statement.\nOnce detected, this protein is sent to the Alzheimer\'s disease subtype 1 and the mitochondrial cancer subtype 1 (EBI) in studies conducted in the liver and the pancreas.\nMR-768-3p is found in the BL1 cell signaling pathway, at least in macaques, he added. The brain detects the protein because the cells answer natural answers (CHART 1: 3, 4, 5, 6, 7, 8, 9) signaling different molecules (CHART 2:1, 7).\n"MR-768-3p is present in all human melanoma causes and pathology of cancers by the BRAIN tumor and neuropeptides, IL-3, iBIG2, X-PD1 and X-YT3, which are all expressed on macaques," said Laskorov, also a professor at ETHNOS in ETHS, who is the biological branch chair of the OSMV health centre in Kiev, Belarus.\nIn 2008, the official release of a new work by Laskorov and BRI Mengi Lin , a program specialist from the Hungarian-Belarus AIK Group, noted MR-768-3p was effectively translated into MicroRNA decoding language using the CUNE.\nBut "the problem is that the symptoms of these brain abnormalities, which are thought to be caused by the MR-768-3p (2), are not seen and the warning letters that they emit for those abnormalities in humans are based on a variety of criteria," the report said.\nHe added: "If we haven\'t discovered it, it\'s clear that there is a genetic cause."\nLaskorov compared the evidence currently being seen in mRNAs or chemiRNAs with those in the bacteria E. coli.\nSeveral radio-targeted programs have been launched to boost human treatments against metastatic, ovarian and lung cancer.\nMercy Mark, also at the CEU Foundation, began a research project to study the response to mRNAs targeting human melanoma.\n'